Loading...

NVCR NOVOCURE LTD Expansion Plans 8-K Filing

NVCR

NVCR

NOVOCURE LTD

(NVCR)

2025 8-K

FDA Approval Granted

Billing Privileges Revoked

Preliminary Financial Results

CEO Resignation Announcement

Financial Results Update

FDA Approval Announcement

Trial Termination

Financial Statements

Clinical Trials

Financial Statements

Product Approval

Financial Results

Preliminary Results

Management Changes

Clinical Trial Success

Management Change

Management Changes

Earnings Reports

Election of Directors

Clinical Trial Results

Financial Results Announcement

Clinical Trial Results

Earnings Release

FDA Approval for Tumor Trea...

Clinical Trial Completion

Earnings Reports

Appointments, Resignations

Business Optimization Plan

Earnings Reports

Earnings Reports

Clinical Trials

Election of Directors

Investor Conferences

Clinical Trial Results

Clinical Trial Results

Earnings Reports

Earnings Reports

Election of New Director

Earnings Reports

Earnings Reports

Positive Clinical Trial Res...

External Links:

NovoCure Ltd announced on September 15, 2025, that Japan's Ministry of Health approved Optune Lua® for use with PD-1/PD-L1 inhibitors in advanced lung cancer treatment. This represents a significant development for the company as it expands its treatment options in Japan.

AI Assistant

NOVOCURE LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.